Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.

Imane El DikaMarinela CapanuJoanne F ChouJames J HardingMichele LyAnna D HrabovskyRichard K G DoJinru ShiaBrittanie MillangJennifer MaEileen M O'Reilly Ghassan K Abou-Alfa

Published in: Cancer medicine (2020)

Sorafenib plus doxorubicin following progression on sorafenib did not show any improved outcome. We do not recommend further development or use of this combination in HCC.

Keyphrases

drug delivery
cancer therapy